146 related articles for article (PubMed ID: 37395024)
1. Expression of m6A RNA Methylation Regulators and Their Clinical Predictive Value in Intrahepatic Cholangiocarcinoma.
Wei F; Zhang JN; Zhao YQ; Lyu H; Chen F
Front Biosci (Landmark Ed); 2023 Jun; 28(6):120. PubMed ID: 37395024
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
3. Development and Validation of an m6A RNA Methylation Regulators-Based Signature for Predicting the Prognosis of Adrenocortical Carcinoma.
Shen C; Liu J; Yang X; Jiao W; Wang Y
Front Endocrinol (Lausanne); 2021; 12():568397. PubMed ID: 33692753
[TBL] [Abstract][Full Text] [Related]
4. Identification of an eight-m6A RNA methylation regulator prognostic signature of uterine corpus endometrial carcinoma based on bioinformatics analysis.
Miao C; Fang X; Chen Y; Zhao Y; Guo Q
Medicine (Baltimore); 2021 Dec; 100(49):e27689. PubMed ID: 34889221
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive characterization of tumor microenvironment and m6A RNA methylation regulators and its effects on PD-L1 and immune infiltrates in cervical cancer.
Ji H; Zhang JA; Liu H; Li K; Wang ZW; Zhu X
Front Immunol; 2022; 13():976107. PubMed ID: 36091006
[TBL] [Abstract][Full Text] [Related]
6. A metabolism-related 4-lncRNA prognostic signature and corresponding mechanisms in intrahepatic cholangiocarcinoma.
Zou W; Wang Z; Wang F; Li L; Liu R; Hu M
BMC Cancer; 2021 May; 21(1):608. PubMed ID: 34034689
[TBL] [Abstract][Full Text] [Related]
7. Exploration and validation of a novel ferroptosis-related gene signature predicting the prognosis of intrahepatic cholangiocarcinoma.
Yao X; Chen B; Wang M; Zhang S; He B; Shi Z; Deng T; Bao W; Wang Y; Chen G; Bo Z
Acta Biochim Biophys Sin (Shanghai); 2022 Sep; 54(9):1376-1385. PubMed ID: 36111744
[TBL] [Abstract][Full Text] [Related]
8. Identification of a Two-m6A RNA Methylation Regulator Risk Signature as an Independent Prognostic Biomarker in Papillary Renal Cell Carcinoma by Bioinformatic Analysis.
Yang F; Zhao G; Ge L; Song Y; Hong K; Zhang H; Liu C; Hong P; Ma L
Biomed Res Int; 2021; 2021():4582082. PubMed ID: 33628782
[TBL] [Abstract][Full Text] [Related]
9. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
[TBL] [Abstract][Full Text] [Related]
10. The pan-cancer analysis of the two types of uterine cancer uncovered clinical and prognostic associations with m6A RNA methylation regulators.
Zou Z; Zhou S; Liang G; Tang Z; Li K; Tan S; Zhang X; Zhu X
Mol Omics; 2021 Jun; 17(3):438-453. PubMed ID: 34110327
[TBL] [Abstract][Full Text] [Related]
11. Immune-related RNA signature predicts outcome of PD-1 inhibitor-combined GEMCIS therapy in advanced intrahepatic cholangiocarcinoma.
Zeng TM; Pan YF; Yuan ZG; Chen DS; Song YJ; Gao Y
Front Immunol; 2022; 13():943066. PubMed ID: 36159865
[TBL] [Abstract][Full Text] [Related]
12. N6-methyladenosine-modified circSLCO1B3 promotes intrahepatic cholangiocarcinoma progression via regulating HOXC8 and PD-L1.
Li J; Xu X; Xu K; Zhou X; Wu K; Yao Y; Liu Z; Chen C; Wang L; Sun Z; Jiao D; Han X
J Exp Clin Cancer Res; 2024 Apr; 43(1):119. PubMed ID: 38641828
[TBL] [Abstract][Full Text] [Related]
13. VIRMA facilitates intrahepatic cholangiocarcinoma progression through epigenetic augmentation of TMED2 and PARD3B mRNA stabilization.
Xu H; Lin X; Li Z; He X; Li Y; Qiu L; Lu L; Liu B; Zhan M; He K
J Gastroenterol; 2023 Sep; 58(9):925-944. PubMed ID: 37391589
[TBL] [Abstract][Full Text] [Related]
14. The significance of m6A RNA methylation modification in prognosis and tumor microenvironment immune infiltration of cervical cancer.
Guo Y; Bai Y; Wang L; Xu Z; Wang X; Wang W
Medicine (Baltimore); 2022 Jul; 101(26):e29818. PubMed ID: 35777046
[TBL] [Abstract][Full Text] [Related]
15. m6A RNA methylation-mediated upregulation of HLF promotes intrahepatic cholangiocarcinoma progression by regulating the FZD4/β-catenin signaling pathway.
Xiang D; Gu M; Liu J; Dong W; Yang Z; Wang K; Fu J; Wang H
Cancer Lett; 2023 Apr; 560():216144. PubMed ID: 36958694
[TBL] [Abstract][Full Text] [Related]
16. Expression patterns and prognostic value of m6A RNA methylation regulators in adrenocortical carcinoma.
Fu Y; Sun S; Bi J; Kong C; Yin L
Medicine (Baltimore); 2021 Mar; 100(10):e25031. PubMed ID: 33725886
[TBL] [Abstract][Full Text] [Related]
17. Identification of clinical prognostic features of esophageal cancer based on m6A regulators.
Wang H; Zhang Y; Chen L; Liu Y; Xu C; Jiang D; Song Q; Wang H; Wang L; Lin Y; Chen Y; Chen J; Xu Y; Hou Y
Front Immunol; 2022; 13():950365. PubMed ID: 36159855
[TBL] [Abstract][Full Text] [Related]
18. M6A regulator expression patterns predict the immune microenvironment and prognosis of non-small cell lung cancer.
Liu X; Ma C; Liu H; Sun Z; Luo J
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2803-2814. PubMed ID: 35596010
[TBL] [Abstract][Full Text] [Related]
19. Identification of a New m6A Regulator-Related Methylation Signature for Predicting the Prognosis and Immune Microenvironment of Patients with Pancreatic Cancer.
Zou T; Shi D; Wang W; Chen G; Zhang X; Tian Y; Gong P
Mediators Inflamm; 2023; 2023():5565054. PubMed ID: 37181810
[TBL] [Abstract][Full Text] [Related]
20. Integrative Analysis of m6A RNA Methylation Regulators and the Tumor Immune Microenvironment in Non-Small-Cell Lung Cancer.
Zhu J; Jiang Y; Wang T; Wu A; Zhou T; Zhang A; Tang Y; Shen Z; Wang J; Zhou H; Shi J; Chen J
Dis Markers; 2022; 2022():2989200. PubMed ID: 35186164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]